Author

Ivan J. Stone

Observed names: I J Stone, I. Stone, I.J. Stone, Ivan Stone

Observed institution: Seagen (United States)

ORCID: 0000-0001-9400-5424

Observed ORCID: 0000-0001-9400-5424

OpenAlex ID: A5065128818

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

2013 · May S. Kung Sutherland, Roland B. Walter, et al. · Blood · 394

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

2013 · Scott C. Jeffrey, Patrick J. Burke, et al. · Bioconjugate Chemistry · 247

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment

2006 · C. F. McDonagh, E. Turcott, et al. · Protein Engineering Design and Selection · 245

Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates

2006 · Scott C. Jeffrey, Jamie B. Andreyka, et al. · Bioconjugate Chemistry · 193

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

2016 · Patrick J. Burke, Joseph Z. Hamilton, et al. · Molecular Cancer Therapeutics · 159

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

2007 · Ezogelin Oflazoglu, Ivan J. Stone, et al. · Blood · 120

PDF

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

2008 · Ezogelin Oflazoglu, Ivan J. Stone, et al. · Clinical Cancer Research · 115

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

2017 · Fu Li, May Kung Sutherland, et al. · Molecular Cancer Therapeutics · 106

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

2006 · Julie A. McEarchern, Ezogelin Oflazoglu, et al. · Blood · 106

A coiled-coil masking domain for selective activation of therapeutic antibodies

2019 · Vivian H. Trang, Xinqun Zhang, et al. · Nature Biotechnology · 96

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

2008 · Charlotte F. McDonagh, Kristine M. Kim, et al. · Molecular Cancer Therapeutics · 96

Anti-CD30 diabody-drug conjugates with potent antitumor activity

2008 · Kristine M. Kim, Charlotte F. McDonagh, et al. · Molecular Cancer Therapeutics · 93

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

2017 · Fu Li, Michelle Ulrich, et al. · Molecular Cancer Therapeutics · 88

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

2009 · Hans-Peter Gerber, May Kung-Sutherland, et al. · Blood · 85

PDF

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

2008 · E Oflazoglu, I J Stone, et al. · British Journal of Cancer · 82

PDF

Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates

2016 · Patrick J. Burke, Joseph Z. Hamilton, et al. · Molecular Cancer Therapeutics · 64

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

2023 · Rebecca Mazahreh, Marsha L. Mason, et al. · Molecular Cancer Therapeutics · 28

PDF

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

2015 · May S.K. Sutherland, Changpu Yu, et al. · Blood · 22

Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma

2016 · Tim Lewis, Devra J. Olson, et al. · Cancer Research · 18

Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation

2020 · Joseph Z. Hamilton, Thomas A. Pires, et al. · ChemMedChem · 17

PDF

SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30+ Malignancies.

2005 · Kevin J. Hamblett, Jeremy Barton, et al. · Blood · 17

Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells

2011 · T S Lewis, R S McCormick, et al. · Leukemia · 16

Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL)

2014 · Sharsti Sandall, Martha Anderson, et al. · Cancer Research · 11

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

2012 · May S.K. Sutherland, Roland B. Walter, et al. · Blood · 10

The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling.

2007 · Timothy S. Lewis, Renee S. McCormick, et al. · Blood · 6

Works count: 104

Citation count: 2,458

H-index: 18

I10-index: 24